Table 2.
Prevalence of abnormal blood pressure and biochemical measurements (N = 41).
| VARIABLE | PRE (%) | POST (%) |
|---|---|---|
| Systolic blood pressure | ||
| Normal (<90th percentile) | 20 (48) | 27 (66) |
| Elevated (≥90th–<95th percentile) | 7 (17) | 6 (15) |
| Hypertension stage 1 (≥95th percentile) | 8 (20) | 7 (17) |
| Hypertension stage 2 (≥95th percentile + 12 mmHg) | 6 (15) | 1 (2) |
| Diastolic blood pressure | ||
| Normal (<90th percentile) | 32 (78) | 35 (86) |
| Elevated (≥90th–<95th percentile) | 1 (2) | 0 (0) |
| Hypertension stage 1 (≥95th percentile) | 8 (20) | 5 (12) |
| Hypertension stage 2 (≥95th percentile + 12 mmHg) | 0 (0) | 1 (2) |
| Blood pressure | ||
| Normal (<90th percentile) | 17 (41) | 24 (59) |
| Elevated (≥90th–<95th percentile) | 8 (20) | 6 (15) |
| Hypertension stage 1 (≥95th percentile) | 10 (24) | 10 (24) |
| Hypertension stage 2 (≥95th percentile + 12 mmHg) | 6 (15) | 1 (2) |
| ALT (Males: >31, Female: >25 U/L) | 2 (5) | 2 (5) |
| HDL-C (≤1.2 mmol/L) | 10 (24) | 9 (23) |
| LDL-C (≥2.8 mmol/L) | 12 (29) | 7 (17) |
| TG (≥1.0 mmol/L) | 5 (12) | 3 (7) |
| Insulin (≥20 mU/ml) | 7 (17) | 5 (12) |
| HOMA-IR (≥3.4) | 6 (15) | 5 (12) |
ALT – Alanine aminotransferase; HDL-C – High-density lipoprotein cholesterol; LDL-C – Low-density lipoprotein cholesterol; HOMA-IR – Homeostatic model assessment of insulin resistance; TG – Triglycerides.